Company Filing History:
Years Active: 2000-2005
Title: **Innovative Contributions of Inventor Shin Yonehara**
Introduction
Shin Yonehara, an accomplished inventor based in Kyoto, Japan, has made significant strides in the field of biotechnology. With two patents to his name, his innovative work focuses primarily on therapeutic advancements that target autoimmune conditions. His inventions have the potential to alter treatment methodologies for various diseases, particularly those related to the Fas/Fas ligand system.
Latest Patents
One of his most notable patents is related to **Anti-Fas antibodies**. This invention includes antibodies that are cross-reactive with both mouse and human Fas, which are highly useful in addressing conditions attributable to abnormalities in the Fas/Fas ligand system. Another key patent is a **therapeutic agent for rheumatic disease**, which comprises an anti-Fas monoclonal antibody, or the combination of this antibody with a medical substance that inhibits cell proliferation. This therapeutic agent specifically reacts with the Fas antigen found in synovial cells of patients suffering from rheumatoid arthritis, thereby inducing apoptosis in these cells.
Career Highlights
Yonehara has worked with renowned companies in the pharmaceutical industry, including Santen Pharmaceutical Co., Ltd. and Sankyo Company, Limited. His experiences in these organizations have likely shaped his innovative mindset and equipped him with the necessary skills to tackle complex medical challenges through his inventions.
Collaborations
Throughout his career, Yonehara has collaborated with distinguished professionals, including Kusuki Nishioka and Nobufusa Serizawa. These collaborations have fostered a productive environment for innovation, enabling the development of groundbreaking therapeutic solutions.
Conclusion
Shin Yonehara's contributions to the field of biotechnology through his patents are a testament to his expertise and innovative thinking. His work has the potential to significantly impact treatments for autoimmune diseases, highlighting the importance of continued research and development in this vital area of healthcare.